BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1898 related articles for article (PubMed ID: 28076709)

  • 21. Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis.
    Kaderli RM; Spanjol M; Kollár A; Bütikofer L; Gloy V; Dumont RA; Seiler CA; Christ ER; Radojewski P; Briel M; Walter MA
    JAMA Oncol; 2019 Apr; 5(4):480-489. PubMed ID: 30763436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The radiosensitizer Onalespib increases complete remission in
    Lundsten S; Spiegelberg D; Raval NR; Nestor M
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):980-990. PubMed ID: 31912256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy: Commercial Parenteral Nutrition Formulas Versus Compounded Arginine/Lysine.
    Al-Toubah T; Sikaria D; Jesurajan J; Bottiglieri S; Smith J; Pellé E; Hutchinson T; Strosberg J; El-Haddad G
    Pancreas; 2021 Apr; 50(4):513-515. PubMed ID: 33939662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Everolimus Combined with
    Aljubran A; Badran A; Alrowaily M; Raef H; Alzahrani AM; Almuhaideb A; Almanea H; El-Dali A; Tuli M; Bazarbashi S
    Cancer Biother Radiopharm; 2024 Mar; 39(2):164-168. PubMed ID: 36342790
    [No Abstract]   [Full Text] [Related]  

  • 25. 177 Lu-DOTATATE Salvage Therapy in Rapidly Progressing Neuroendocrine Tumor With Poor Performance Status.
    Aggarwal P; Kumar A; Sood A; Walia R; Bhadada SK; Mittal BR
    Clin Nucl Med; 2024 Jun; 49(6):561-563. PubMed ID: 38498693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.
    de Vries-Huizing DMV; Cheung ZJ; Hendrikx JJMA; Donswijk ML; Versleijen MWJ
    Clin Nucl Med; 2024 May; 49(5):454-456. PubMed ID: 38465961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
    Singh S; Ferone D; Capdevila J; Chan JA; de Herder WW; Halperin D; Mailman J; Hellström L; Liedman H; Svedberg A; Tiberg F
    Trials; 2024 Jan; 25(1):58. PubMed ID: 38229199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term clinical outcomes of [
    Iqbal S; Zhuang E; Raj M; Bahary N; Monga DK
    Front Oncol; 2024; 14():1393317. PubMed ID: 38817893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.
    Strosberg JR; Al-Toubah T; El-Haddad G; Reidy Lagunes D; Bodei L
    J Nucl Med; 2024 Mar; 65(3):340-348. PubMed ID: 38238038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with
    Parghane RV; Basu S
    J Nucl Cardiol; 2020 Feb; 27(1):340-341. PubMed ID: 30151794
    [No Abstract]   [Full Text] [Related]  

  • 31. Letter to the editor regarding "The effect of long-acting somatostatin analogs on the uptake of [
    Wang R; Guo L; Shen G
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):180-182. PubMed ID: 37561142
    [No Abstract]   [Full Text] [Related]  

  • 32. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.
    Brizzi MP; Berruti A; Ferrero A; Milanesi E; Volante M; Castiglione F; Birocco N; Bombaci S; Perroni D; Ferretti B; Alabiso O; Ciuffreda L; Bertetto O; Papotti M; Dogliotti L
    BMC Cancer; 2009 Nov; 9():388. PubMed ID: 19886987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.
    Lubner S; Feng Y; Mulcahy M; O'Dwyer P; Giang GY; Hinshaw JL; Deming D; Klein L; Teitelbaum U; Payne J; Engstrom P; Stella P; Meropol N; Benson A
    Oncologist; 2018 Sep; 23(9):1006-e104. PubMed ID: 29853660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide.
    Low HC; Tay YS; Ong SYK; Tham WY; Yan SX
    Clin Nucl Med; 2023 Dec; 48(12):1086-1088. PubMed ID: 37844418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 stabilisation potentiates [
    Berglund H; Salomonsson SL; Mohajershojai T; Gago FJF; Lane DP; Nestor M
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):768-778. PubMed ID: 37823909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
    Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
    Am J Clin Oncol; 2022 Jun; 45(6):233-242. PubMed ID: 35507413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
    Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
    J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial Findings on the Use of [
    Demirci E; Alan Selçuk N; Beydağı G; Ocak M; Toklu T; Akçay K; Kabasakal L
    Mol Imaging Radionucl Ther; 2023 Oct; 32(3):226-232. PubMed ID: 37870290
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Donzé C; Rubira L; Santoro L; Viarasakd M; Kotzki PO; Deshayes E; Fersing C
    Eur J Hosp Pharm; 2024 Apr; 31(3):207-211. PubMed ID: 36100369
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 95.